secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2021-11-22T23:59:59+00:00
Accession:  0001193125-21-336764
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis appoints Prathyusha Duraibabu to board, regains Nasdaq audit committee compliance
--------------------------------------------------------------------------------

- Prathyusha Duraibabu appointed independent director effective Nov 19, 2021; also joins audit committee.
- Board now has eight members; appointment restores compliance with Nasdaq Listing Rule 5605(c)(2)(A).
- Ms. Duraibabu received 11,340 RSUs vesting in equal annual installments over three years.
- She is CFO of Sangamo Therapeutics; brings 24+ years in tech/healthcare and CPA qualification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312521336764/0001193125-21-336764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312521336764/d210033d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-336764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer